September 20, 2013
Mayo Clinic Researchers Identify Biomarker For Smoker’s Lung Cancer
Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.
"This is exciting because we've found what we believe to be a 'drugable target' here," says George Vasmatzis, Ph.D., a Mayo Clinic molecular medicine researcher and senior author on the study. "It's a clear biomarker for aggressive adenocarcinomas. These are the fast-growing cancer cells found in smokers' lungs."
When researchers blocked the ASCL1 protein in lung cancer cell lines expressing both genes, the level of RET decreased and tumor growth slowed. This leads researchers to believe this mechanism will be a promising target for potential drugs and a strong candidate for clinical trials.
On the Net: